In an open letter, the hedge fund accuses Novavax’s leadership of squandering its “many significant competitive advantages ...
At last month’s Reuters Pharma USA conference in Philadelphia, pharmaphorum’s Jonah Comstock caught up with Serena Goodwin, a ...
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its ...
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral ...
Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer ...
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA ...
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign ...
A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, ...
GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 ...
From launch strategy and commercializing gene therapy to digital tools and the dying hype over GenAI, to a data-driven Medical Affairs future and unveiling the patient-centric paradigm, as well as ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now ...
There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to ...